D. Has Simsek Et Al. , "Can PSMA-based tumor burden predict response to docetaxel treatment in metastatic castration-resistant prostate cancer?," Annals of Nuclear Medicine , vol.35, no.6, pp.680-690, 2021
Has Simsek, D. Et Al. 2021. Can PSMA-based tumor burden predict response to docetaxel treatment in metastatic castration-resistant prostate cancer?. Annals of Nuclear Medicine , vol.35, no.6 , 680-690.
Has Simsek, D., Kuyumcu, S., Karadogan, S., Oflas, M., Isik, E. G., Ozkan, Z. G., ... Paksoy, N.(2021). Can PSMA-based tumor burden predict response to docetaxel treatment in metastatic castration-resistant prostate cancer?. Annals of Nuclear Medicine , vol.35, no.6, 680-690.
Has Simsek, Duygu Et Al. "Can PSMA-based tumor burden predict response to docetaxel treatment in metastatic castration-resistant prostate cancer?," Annals of Nuclear Medicine , vol.35, no.6, 680-690, 2021
Has Simsek, Duygu H. Et Al. "Can PSMA-based tumor burden predict response to docetaxel treatment in metastatic castration-resistant prostate cancer?." Annals of Nuclear Medicine , vol.35, no.6, pp.680-690, 2021
Has Simsek, D. Et Al. (2021) . "Can PSMA-based tumor burden predict response to docetaxel treatment in metastatic castration-resistant prostate cancer?." Annals of Nuclear Medicine , vol.35, no.6, pp.680-690.
@article{article, author={Duygu Has Simsek Et Al. }, title={Can PSMA-based tumor burden predict response to docetaxel treatment in metastatic castration-resistant prostate cancer?}, journal={Annals of Nuclear Medicine}, year=2021, pages={680-690} }